TECX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 7.88%, SMA50 14.67%, SMA200 18.2%). The stock’s 14-day RSI is 61.43 (firm momentum), while the ATR of 2.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.44% below its high and over 74.67% above its low. Average 10-day trading volume of 192.09 thousand shares is in line with the 3-month average of 205.45 thousand, indicating normal recent market interest.

Tectonic Therapeutic, Inc. generated EPS of -$3.85 over the past year. Five-year average earnings growth is 26.54%. Wall Street analysts project EPS growth of 8.0% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $81.00 to $64.00. The high target offers 200.0% upside. The low target suggests 137.04% downside. The mean target is $73.33. This offers 171.59% upside. Tectonic Therapeutic, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -12.51%. The prior quarter beat by 15.52%. Over the last six quarters, Apple has recorded several small beats. These include -15.45% in May 08, 2025.

Tectonic Therapeutic, Inc. has 18.87 million shares outstanding. The public float is 11.23 million shares, elevated short interest at 21.55% of float. This equals 1.94 million shares. The short ratio is 9.71 days. Institutional investors hold 115.43% of the float. Insiders own 37.85%. SPRINGER TIMOTHY A holds 1.50 million shares, MCGUIRE TERRANCE has 573.06 thousand shares and REICIN ALISE has 127.03 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.32 thousand shares across 5 transactions.

Tectonic Therapeutic, Inc. (NASDAQ:TECX) closed at $27.00 USD, losing -$0.21 (-0.77%) from the previous close of $27.21. The stock is currently mid-range between its 52-week high and low $14.39 and $39.53. With a market capitalization of about $509.47 million, Tectonic Therapeutic, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.22). Key stats such as the average daily volume over the past year has been around 205.06 thousand shares, trading with heavier-than-usual volume. Headquartered in Watertown, MA, Tectonic Therapeutic, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alise S. Reicin, the company employs approximately 60 people and listed since June 21, 2018. Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs).

Tectonic Therapeutic, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.78. This means the shares are trading above this model’s fair value.

Tectonic Therapeutic, Inc. trades at a P/E ratio of -5.98, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.32 suggesting the stock is closer to book value. The P/FCF stands at -7.12, also below market averages.

Our AI price prediction model suggests that Tectonic Therapeutic, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.93%, with price expected at $22.16 by October 01, 2026, within a range of $20.04 to $24.16 3-Month Outlook: Projected rise of 76.59%, reaching $47.68 by December 16, 2026, with a range of $43.18 to $50.97. 1-Year Outlook: Projected gain of 19.67%, with price at $32.31 by September 17, 2027, within a range of $28.78 to $35.23.

Tectonic Therapeutic, Inc. (NASDAQ:TECX) shares are flat -8.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tectonic Therapeutic, Inc. trading at a premium to the broader market with a P/E of -5.98. Analyst sentiment is cautious, with the majority of ratings in Strong Buy territory and a mean price target of $74.09, suggesting 174.41% upside. Our AI forecast model points to short-term weakness (-17.93% over two weeks), a medium-term rise (76.59% over three months), and a longer-term gain (19.67% over one year), with expected trading ranges indicating moderate volatility.